A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.
Debashis Sarker(King's College - North Carolina), Sophie Glatt(UCB Pharma (United Kingdom)), Nieves Díaz(UCB Pharma (United Kingdom)), Elizabeth Ruth Plummer, Ann Cleverly(UCB Pharma (United Kingdom)), Sarah P. Blagden(Churchill Hospital), Natalie Cook(Manchester Academic Health Science Centre), Ivan Matthews(UCB Pharma (United Kingdom)), Paul S. Jones(Cancer Research UK), T.R. Jeffry Evans(University of Glasgow), Marina Braun(University of Veterinary Medicine Hannover, Foundation), Udai Banerji(Institute of Cancer Research)
Cited by 2
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222